Advances in antibody-mediated immunity against Mycobacterium tuberculosis: Implications for a novel vaccine strategy

Aharona Glatman-Freedman*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

43 Scopus citations

Abstract

Cell-mediated immunity is considered to be the major component of the host response against Mycobacterium tuberculosis, whereas antibody-mediated immunity historically has been considered inconsequential. In recent years, studies from several groups have challenged the traditional dogma and demonstrated that monoclonal antibodies can modify various aspects of mycobacterial infections. This review describes the experimental evidence supporting a role for antibodies in defense against mycobacterial infections and outlines future challenges to the field of antibody-mediated immunity against M. tuberculosis, with particular emphasis on the implications of these findings for a novel vaccine strategy.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalFEMS Immunology and Medical Microbiology
Volume39
Issue number1
DOIs
StatePublished - 24 Oct 2003
Externally publishedYes

Funding

FundersFunder number
National Institute of HealthAI001691, AI053192
National Institute of Allergy and Infectious DiseasesK08AI001691
National Institute of Allergy and Infectious Diseases

    Keywords

    • Antibody-mediated immunity
    • Monoclonal antibody
    • Mycobacterium tuberculosis
    • Mycobacterium tuberculosis vaccine

    Fingerprint

    Dive into the research topics of 'Advances in antibody-mediated immunity against Mycobacterium tuberculosis: Implications for a novel vaccine strategy'. Together they form a unique fingerprint.

    Cite this